Solventum Corporation (NYSE:SOLV) Receives $85.56 Consensus PT from Brokerages

by · The Cerbat Gem

Solventum Corporation (NYSE:SOLV – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $87.00.

SOLV has been the topic of several research reports. Piper Sandler raised their price target on Solventum from $94.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Zacks Research downgraded shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Finally, Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Monday, December 1st.

Read Our Latest Research Report on Solventum

Solventum Stock Performance

Shares of NYSE:SOLV opened at $85.41 on Monday. The firm’s 50 day simple moving average is $75.10 and its 200-day simple moving average is $74.06. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum has a one year low of $60.70 and a one year high of $88.20. The firm has a market cap of $14.81 billion, a PE ratio of 9.84, a price-to-earnings-growth ratio of 9.00 and a beta of 0.26.

Solventum (NYSE:SOLV – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.Solventum’s revenue was up .7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, equities analysts predict that Solventum will post 6.58 EPS for the current year.

Solventum declared that its Board of Directors has initiated a share buyback plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Solventum

Institutional investors have recently added to or reduced their stakes in the stock. Strengthening Families & Communities LLC lifted its position in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of Solventum during the 3rd quarter worth approximately $25,000. Deseret Mutual Benefit Administrators raised its stake in shares of Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock worth $27,000 after acquiring an additional 163 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new stake in Solventum during the second quarter valued at approximately $28,000. Finally, Barrett & Company Inc. boosted its stake in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares in the last quarter.

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Featured Articles